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ABSTRACT
Background Variability in endoscopic assessment
necessitates rigorous investigation of descriptors for
scoring severity of ulcerative colitis (UC).
Objective To evaluate variation in the overall endoscopic
assessment of severity, the intra- and interindividual
variation of descriptive terms and to create an Ulcerative
Colitis Endoscopic Index of Severity which could be
validated.
Design A two-phase study used a library of 670 video
sigmoidoscopies from patients with Mayo Clinic scores
0e11, supplemented by 10 videos from ﬁve people
without UC and ﬁve hospitalised patients with acute
severe UC. In phase 1, each of 10 investigators viewed
16/24 videos to assess agreement on the Baron score
with a central reader and agreed deﬁnitions of 10
endoscopic descriptors. In phase 2, each of 30 different
investigators rated 25/60 different videos for the
descriptors and assessed overall severity on a 0e100
visual analogue scale. k Statistics tested inter- and
intraobserver variability for each descriptor. A general
linear mixed regression model based on logit link and
b distribution of variance was used to predict overall
endoscopic severity from descriptors.
Results There was 76% agreement for ‘severe’, but 27%
agreement for ‘normal’ appearances between phase I
investigators and the central reader. In phase 2,
weighted k values ranged from 0.34 to 0.65 and 0.30 to
0.45 within and between observers for the 10
descriptors. The ﬁnal model incorporated vascular
pattern, (normal/patchy/complete obliteration) bleeding
(none/mucosal/luminal mild/luminal moderate or severe),
erosions and ulcers (none/erosions/superﬁcial/deep),
each with precise deﬁnitions, which explained 90% of
the variance (pR
2, Akaike Information Criterion) in the
overall assessment of endoscopic severity, predictions
varying from 4 to 93 on a 100-point scale (from normal
to worst endoscopic severity).
Conclusion The Ulcerative Colitis Endoscopic Index of
Severity accurately predicts overall assessment of
endoscopic severity of UC. Validity and responsiveness
need further testing before it can be applied as an
outcome measure in clinical trials or clinical practice.
INTRODUCTION
Endoscopy plays a pivotal role in the evaluation of
ulcerative colitis (UC). At least nine different
scoring systems are used as outcome measures in
clinical trials, and endoscopy has an important role
in most.
1 2 Indices are typically composite measures
that include assessment of symptom severity,
quality of life, laboratory tests and endoscopic
ﬁndings. However, the contribution of endoscopy is
index-speciﬁc. In the widely used Mayo Clinic
index,
2 endoscopy is one of four criteria and just
one of two criteria (in addition to rectal bleeding)
currently used by the Food and Drug Administra-
tion for deﬁning remission. Consequently, interob-
server variation in assessing endoscopic activity is
important, because disagreement can alter the
proportion of patients deﬁned as in remission and
inﬂuence regulatory decisions.
The original endoscopic grading of UC (Baron
index, 1964) was developed before index method-
ology was deﬁned.
3 It has been used, nevertheless,
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Signiﬁcance of this study
What is already known about this subject?
< There is wide variation in the endoscopic
assessment of the severity of ulcerative colitis.
< There is no validated instrument.
What are the new ﬁndings?
< An indexdthe Ulcerative Colitis Endoscopic
Index of Severitydwith three descriptors
(vascular pattern, bleeding and ulceration) has
been developed that captures 90% of the
variance of the overall assessment of endo-
scopic severity.
< The three descriptors are each graded in three or
four levels with precise deﬁnitions.
< Friability is excluded from the endoscopic
description of severity.
How might this impact on clinical practice?
< Once independently validated, the Ulcerative
Colitis Endoscopic Index of Severity will be
available for clinical trials, training and practice.
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Inﬂammatory bowel diseasein most trials of active UC to this day, with only minor and
unvalidated modiﬁcation.
2 Data supporting the index are scant.
It was created by scoring seven endoscopic descriptors in 60
patients, by three observers using rigid sigmoidoscopes. The k
statistic, a measure of interobserver agreement, was not calcu-
lated and there was 40% disagreement when grading normal,
mild, moderate or severe activity. Efforts have since been made
to standardise endoscopic assessment
3 by using the presence of
mucosal friability to discriminate between mild (Baron level 1)
and moderately active (Baron level 2) disease.
4e6
Variation between observers in categorising endoscopic disease
activity is widely suspected,
1 27 e10 so the need for this to be
quantiﬁed appears self-evident. The aims of this study were ﬁrst
to substantiate variation in endoscopic assessment of activity in
UC, then to evaluate intra- and interindividual variation of
descriptive terms and, ﬁnally, to create an Ulcerative Colitis
Endoscopic Index of Severity (UCEIS) which could be validated.
METHODS
The study included two phases. Phase 1 mapped inconsistencies
in endoscopic assessment and deﬁned the most dependable
descriptive terms (‘descriptors’). Phase 2 quantiﬁed inter- and
intraobserver variation in these descriptors, in order to construct
an index (UCEIS) that could be validated. For consistency in the
text, the word ‘index’ refers to an instrument for assessing
activity; ‘descriptor’ refers to an item within that index with
severity allocated on a Likert scale; and ‘level’ is used to refer to
the severity graded for an item. ‘Score’ is the overall measure
provided by an index. Common usage has often confused these
terms, but they are used as consistently as possible in this paper.
Phase 1
Ten specialists in inﬂammatory bowel disease (IBD, the authors)
graded videos of ﬂexible sigmoidoscopy according to their own
practice, in the absence of clinical information. Twenty-four
representative videos were selected to represent the widest range
of UC activity, guided by the Mayo Clinic score (by PK and
BRY) from a library of 670 videos recorded in a standard manner
during clinical trials for the treatment of moderately active UC
6
(EUDRACT 2006-001310-32). Within each Mayo Clinic score
stratum, consecutive videos were reviewed by one of the co-
authors for image quality. Satisfactory quality recordings (sharp
image, sufﬁcient bowel preparation) were selected. Videos from
ﬁbreoptic endoscopes were discarded. Sixteen videos represented
the complete range of severity; 24 videos enabled choice from
additional videos in the mid-range of severity, most likely to be
affected by interobserver variation. Each investigator was
randomly assigned 16 of the 24 videos in randomised order using
a set of Latin squares: a core set of eight videos that all inves-
tigators evaluated (two for each Baron score) and eight of 16
non-core videos, This kept the number of evaluations by each
investigator in the 2e3 h session to a manageable number (16),
while still having a common core set (8) and a broad overall pool
of videos (24). Investigators were explicitly advised not to apply
the Baron index themselves, to avoid biasing their overall
assessment of severity in relation to this index. To assess
potential scoring differences based on the length of the video,
11
each investigator had two pairs that were shortened from
10e15 min to approximately 5 min, giving a total of 18 videos
for each investigator to view. Descriptors of endoscopic severity
were selected from previous studies.
3891 21 3Investigators
recorded the presence or absence of 11 descriptors. Overall
severity was assessed on a visual analogue scale (VAS, between
0¼completely normal and 100¼worst ever seen).
To substantiate variability in endoscopic assessment, the level
of the Baron index derived from the assessments by investigators
was compared with the level assigned by the central reader in
the original trial.
7 The precise wording of deﬁnitions and video
clips illustrating anchor points on three-, four- or ﬁve-point
Likert scales of severity for each descriptor, were subsequently
agreed by consensus during a video teleconference between
investigators (table 1).
Phase 2
Fifty core videos were assembled, 40 from the library of 670
videos (by PK and BRY, representing Mayo Clinic levels (scores)
0e11, different from those selected for phase 1), representing six
expected severity strata (note selection criteria for phase 1). A
further ﬁve from individuals without UC and ﬁve from patients
hospitalised with severe UC who had consented to their
anonymised images being used for study (Oxford LREC
536407Q1605/58ORH), represented two additional strata at the
expected extremes of endoscopic severity. The ﬁve patients
admitted with biologically severe UC represented the most
severe end of the spectrum of UC, although only 2/5 came for
colectomy (one within 6 h of ﬂexible sigmoidoscopy). To eval-
uate the Contact Friability Test (CFT), 10 different videos
representing Mayo Clinic levels 1e11, two for each stratum,
were amended to exclude CFT sequences and paired with the
complete video showing the CFT.
Each of 30 new investigators from 13 countries, including 19
from the USA and Canada (see ‘Acknowledgements’) scored 25
videos selected from the 60 recordings, but blinded to clinical
information or Mayo Clinic score. Endoscopists were recruited
to reﬂect a range of geographical and institutional characteris-
tics, from investigators with endoscopic training in trials of IBD
or known to the authors as having an interest in endoscopy or
IBD (840 median colonoscopies and ﬂexible sigmoidoscopies/
year (range 100e2100), median 25 years’ endoscopy experience,
range 8e35). Each investigator was randomly allocated
a CDROM containing 15/40 core videos from the library
(comprising two to three videos selected from each of the six
Mayo Clinic levels), two out of ﬁve normal videos from people
without UC and two out of ﬁve videos from patients with
severe UC, together with two out of 10 CFT+/  pairs (table 2).
To evaluate intraobserver consistency, each investigator also
scored two of their 13 core videos representing Mayo Clinic
levels 1e11 twice, in random order. Investigators were asked to
score each video using every descriptor in table 1 and to assign
an overall assessment of severity using an electronic 0e100 VAS.
Videos were assigned to investigators using an incomplete
block design, stratiﬁed by expected severity stratum. This
randomisation process meant that each video was scored by
10e12 investigators, except for the four videos in Mayo Clinic
level 0 stratum, which were each viewed by 15 investigators.
Owing to an assignment error, 5/30 investigators were assigned
only one and not two normal videos. The order of endoscopy
evaluation was randomised using a set of Latin squares. Dupli-
cate videos were randomly interspersed in the video set, but
positioned so that they were separated by at least eight other
videos; videos comprising a CFT+/  pair were separated by at
least four other videos and the viewing order balanced. The order
of descriptors was randomised between investigators using Latin
squares so that each descriptor appeared ﬁrst (second, third, etc)
an equivalent number of times across investigators, although the
order was constant for each investigator. Video clips illustrating
each descriptor and anchor points on the Likert scale were
provided and data (descriptors on four- or ﬁve-point Likert scales,
536 Gut 2012;61:535e542. doi:10.1136/gutjnl-2011-300486
Inﬂammatory bowel diseasewith overall assessment of severity by VAS) were collected elec-
tronically using a programmed PalmPilot. The range of endo-
scopic severity was graphically checked by plotting the mean
severity level evaluated by VAS as a function of its rank order.
Statistics
Intraobserver variation was assessed by k statistics
14 calculated
from the two pairs of duplicate videos. Interobserver variation
was stratiﬁed by investigator pairs for the common videos they
Table 1 Descriptors and deﬁnitions
Descriptor (score most severe lesions) Likert scale anchor points Deﬁnition
Vascular pattern Normal (1) Normal vascular pattern with arborisation of capillaries clearly deﬁned
Patchy loss (3) Patchy loss or blurring of vascular pattern
Obliterated (5) Complete loss of vascular pattern
Mucosal erythema None (1) The colour of the mucosa is normal
Light red (3) Some increase in colour of the mucosa that is probably abnormal, but would
be best compared side by side with a normal examination
Dark red (5) Red or crimson colour of the mucosa that is similar to blooddthat is, clearly
abnormal even if not compared with a normal examination (does not include
intramucosal haemorrhage)
Mucosal surface (Granularity) Normal (1) Smooth mucosa with a sharp light reﬂex, similar to a polished surface
Granular (3) Mucosal surface diffuses reﬂected light causing minor variation in the surface
Nodular (5) Evident nodular variation in mucosal surface
Mucosal oedema None (1) Normal appearance: no white or yellow substance visible
Probable (3) Slight swelling and thickening of mucosa
Deﬁnite (5) Marked thickening and oedema of the mucosa with blunting of the mucosal folds
Mucopus None (1) Normal appearance: no white or yellow substance visible
Some (3) White or yellow deposits on the mucosa unrelated to any bowel preparation
Lots (5) Mucopus substantially covering the mucosal surface unrelated to any bowel preparation
Bleeding None (1) No visible blood
Mucosal (2) Some spots or streaks of coagulated blood on the surface of the mucosa ahead
of the scope, which can be washed away
Luminal mild (3) Some free liquid blood in the lumen
Luminal moderate (4) Frank blood in lumen ahead of endoscope or visible oozing from mucosa after
washing intraluminal blood
Luminal severe (5) Frank blood in the same lumen with visible oozing from a haemorrhagic mucosa
Incidental friability None (1) No bleeding or intramucosal haemorrhage before or after passage of the endoscope
Mild (2) No bleeding at the site of assessment before, but minor bleeding or intramucosal
haemorrhage after, passage of the endoscope
Moderate (3) Intramucosal haemorrhage without overt bleeding before passage of the endoscope
Severe (4) Overt bleeding after passage of the endoscope
Very severe (5) Overt bleeding from the mucosa
Contact friability None (1) No bleeding from the mucosa after light touch with closed biopsy forceps
Probable (3) Intramucosal haemorrhage or minor bleeding after light touch with closed biopsy forceps
Deﬁnite (5) Overt bleeding mucosa after light touch (within 10 s) with closed biopsy forceps
Erosions and ulcers None (1) Normal mucosa, no visible erosions or ulcers
Erosions (2) Tiny (#5 mm) defects in the mucosa, of a white or yellow colour with a ﬂat edge
Superﬁcial ulcer (3) Larger (>5 mm) defects in the mucosa, which are discrete ﬁbrin-covered ulcers in
comparison with erosions, but remain superﬁcial
Deep ulcer (4) Deeper excavated defects in the mucosa, with a slightly raised edge
Extent of erosions or ulcers None (1) None seen during endoscopy
Limited (2) <10% of the affected mucosa
Substantial (3) 10%e30% of the affected mucosa
Extensive (4) >30% of the affected mucosa
*An additional descriptor attempted to describe the transition from abnormal to normal mucosa, but was discarded during phase 1 on the basis that it deﬁed deﬁnition. Erosions and ulcers had
four (response) levels while the others had ﬁve because the expert panel were unable to form a range of ﬁve responses with meaningful or measurable distinctions between 2 and 3 or 3 and 4.
Table 2 Distribution and allocation of videos to investigators
Expected severity stratum
Mayo Clinic stratum
Total videos Normal 0 1e23 e56 e78 e91 0 e11 Most severe
Core videos 5 4 68886 5 5 0
Core videos assigned to each investigator 2* 2 23332 2 1 9
Duplicates of core video assigned to investigators ee Each investigator was assigned two videos that
duplicated two core videos from among these strata
e 2
Contact friability videos (One with CFT, one without CFT) ee 22222 e 10
CFT videos assigned to each investigator ee Each investigator was assigned two CFT pairs,
where the CFT+ videos were nominally in these
strata.
e 4
Total readings assigned to each investigator 2* 2 2e43 e53 e53 e52 e42 2 5
One of the videos in the normal stratum was later found to be from a patient, thus there were truly four screening colonoscopies in this stratum.
*Owing to a video error in this stratum, ﬁve readers viewed one instead of two normal videos.
CFT, Contact Friability Test.
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videos, and incomplete data (<5%). An average of investigator-
pair k values (‘overall k’) was calculated, where the weighting
was the inverse of their variance. Two k values were calculated:
the standard k summarising the exact level of agreement and
a weighted k taking into account partial credit for disagreement,
by assigning a weight of 1 for agreeing levels, 0.5 for levels in
adjacent categories on the Likert scale except for the two lowest
levels and 0 for any other level. Qualitative interpretation of k
statistics used the convention of Landis and Koch.
15
Relationships between descriptors and overall severity (VAS)
were explored using generalised linear mixed model (GLM)
regression. GLM regression used the b distribution for variance
and the logit link.
16 The logit link function constrains real
parameters to a value between 0 and 1. Descriptors were
included as categorical variables, so that the contribution of each
level for each descriptor could be explored separately and up to
three-way interactions between descriptors assessed. The
investigator was included as a random effect. The suitability of
models was assessed by plotting least-squares means, examining
residual plots and the Akaike Information Criterion (AIC).
17
Described roughly, the AIC is the log likelihood penalised by the
number of parameters, a large negative value indicating a good
ﬁt in a parsimonious model. An R
2 statistic, denoted pR
2, was
the squared correlation between the logit-transformed overall
severity evaluations on VAS and linear function of predictors
from the model. p Values for tests of speciﬁc terms (eg, inter-
actions) were determined from asymptotic F tests. The strategy
for optimising the number of response levels was to start with
the full number of levels for each item and use the regression
modelling (speciﬁcally AIC and patterns of mean responses) to
identify opportunities to eliminate or combine levels while still
maintaining a strong correspondence to the overall score (VAS).
All statistical analyses were conducted using SAS V.9.2.
RESULTS
Phase 1
Severity ratings by the 10 IBD specialists showed substantial
variation when compared with each other (data not shown),
while Baron scores derived from their ﬁndings did not match
those assigned by a central reader (ﬁgure 1). There was 76%
agreement for ‘severe’ activity, but only 27% agreement for
a normal appearance and 37% for moderate severity among the
videos selected.
6 Ten descriptors (table 1) and full-length
Figure 1 Distribution of levels of Baron score among specialists in the
phase 1 panel as a function of the level assigned by the central reader.
Ten authors of this paper scored the severity of ulcerative colitis
according to their standard practice in 16 videos selected randomly from
a total of 24. A level (rating) of the Baron score was then assigned,
based on their assessment of friability and this was compared with the
level assigned by a central reader. (0¼ normal; 1¼minor; 2¼moderate;
3¼severe endoscopic severity). n, total number of ratings by phase 1
panel; s, number of video sigmoidoscopies.
Figure 2 Mean assessment of overall severity as a function of its rank
among all mean evaluations of severity, based on 750 evaluations
performed by 30 investigators on 25 out of 60 videos. Mean overall
severity on a visual analogue scale ranged from 0.67 (video in the normal
stratum) to 96.4 (in the most severe stratum) across 25 out of 60 videos
scored by 30 investigators, indicating that the videos selected provided
an appropriate range of endoscopic severity.
Table 3 Intra-investigator variation results
Descriptor
Response (%) k
1 2 3 4 5 Standard Weighted
Vascular pattern 3.3 5.0 23.3 11.7 56.7 0.51 0.61
Mucosal erythema 5.0 15.8 39.2 15.8 24.2 0.37 0.43
Mucosal surface 11.7 12.5 35.0 8.3 32.5 0.37 0.45
Mucosal oedema 7.8 11.2 34.5 10.3 36.2 0.33 0.43
Mucopus 30.0 17.5 33.3 8.3 10.3 0.38 0.47
Bleeding 33.3 38.3 15.0 10.0 3.3 0.51 0.57
Incidental friability 24.4 38.3 14.8 15.7 7.0 0.37 0.49
Contact friability (CFT) 23.5 10.8 30.4 8.8 26.5 0.33 0.34
Erosions and ulcers 26.7 32.5 31.7 9.2 e 0.56 0.65
Extent of erosions and ulcers 26.7 32.8 25.9 14.7 e 0.51 0.60
Based on 60 repeat pair assessments (two pairs per investigator) of 36 separate videos with Mayo Clinic scores between 1 and 11. ‘Response’ for each descriptor refers to the percentage of
responses across all assessments. ‘Descriptor’ refers to the descriptive term used for endoscopic assessment (table 1). Columns 1e5 represent levels on the Likert scale of severity for each
item. Erosions and ulcers and extent of erosion and ulcers items had four response levels on the Likert scale; all other items had ﬁve levels.
CFT, Contact Friability Test.
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after phase 1 was that which attempted to describe the transi-
tion from abnormal to normal mucosa, on the basis that it deﬁed
deﬁnition. Short-length videos were excluded, because of varia-
tion in scoring from full-length videos (data not shown) and the
risk of editing out information from the original.
Phase 2
Seven hundred and ﬁfty evaluations were performed on 60
videos by 30 investigators (response rate 100% for overall
assessment of severity by VAS and $96.5% for all descriptors).
Mean overall assessments of endoscopic severity scores ranged
from a VAS of 0.67 (video in the normal stratum) to 96.4
(most severe stratum), suggesting that the 60 videos encom-
passed the range of endoscopic seve r i t ys e e ni nc l i n i c a lp r a c t i c e
(ﬁgure 2).
Intraobserver and interobserver agreement
Sixty repeat pair assessments (two pairs per investigator) of
36 separate videos were assessed for intraobserver variability
(table 3). Weighted intrainvestigator k statistics ranged from
0.34 for contact friability to 0.65 for erosions and ulcers. Six
hundred and thirty assessments of 60 videos (21 per investigator,
excluding duplicates and CFT-) assessed interobserver variability.
Interinvestigator k statistic ranged from 0.30 for contact fria-
bility to 0.45 for erosions and ulcers (table 4). It is notable that
CFT, designed to reduce variation, showed the lowest level of
agreement.
Overall assessment of severity
The mean (95% CI) overall assessment of severity according to
the 100-point VAS for each descriptor and each level of the Likert
scale derived from the GLM model are shown in ﬁgure 3. Some
descriptors (eg, vascular pattern) appear to provide discrimina-
tion for lower levels of severity, with others (eg, bleeding)
discriminating at higher levels of severity.
Table 4 Interinvestigator variation results
Descriptor
Response (%) k
1 2 3 4 5 Standard Weighted
Vascular pattern 11.7 6.8 21.4 8.6 51.4 0.34 0.42
Mucosal erythema 15.6 11.1 36.5 15.7 21.1 0.25 0.35
Mucosal surface 18.9 12.5 31.6 11.7 25.2 0.26 0.34
Mucosal oedema 16.5 12.3 25.7 12.8 32.7 0.23 0.31
Mucopus 37.8 13.3 27.6 8.7 12.5 0.32 0.40
Bleeding 41.9 29.7 14.8 9.0 4.6 0.29 0.37
Incidental friability 30.2 31.5 21.8 9.7 6.9 0.30 0.40
Contact friability (CFT) 25.0 12.8 29.6 7.8 24.7 0.23 0.30
Erosions and ulcers 37.1 27.1 24.8 11.0 e 0.36 0.45
Extent of erosions and ulcers 36.2 21.9 21.3 20.6 e 0.32 0.42
Based on a total of 630 assessments of 60 videos: 21 per investigator with 19 core videos (15 representing Mayo Clinic strata 0e11, two to three per stratum, 2 normal, 2 severe) and two
CFT+ videos (representing Mayo Clinic strata 1e11). ‘Response’ for each descriptor refers to the percentage of responses across all assessments. ‘Descriptor’ refers to the descriptive term
used for endoscopic assessment (table 1). Columns 1e5 represent levels on the Likert scale of severity for each item. Erosions and ulcers and extent of erosion and ulcers items had four
response levels on the Likert scale; all other items had ﬁve levels.
CFT, Contact Friability Test.
Figure 3 Predicted mean overall assessment of severity for each level
of each descriptor. Assessment of overall severity using a 100 point
visual analogue scale for each level on the Likert scale of severity for
each descriptor (table 1). Predictors are based on generalised linear
mixed modelling, using logit link, b distribution for variance, investigator
as a random effect and descriptors one by one as categorical variables.
Table 5 Generalised linear mixed models with one, two and three
descriptors
Number of descriptors Descriptors used (number of levels) AIC pR
2
1 Erosions and ulcers (4)
Mucosal erythema (5)  607 0.57
Mucosal oedema (5)  582 0.55
Vascular pattern (5)  561 0.57
Incidental friability (5)  495 0.49
Bleeding (5)  437 0.44
2 Erosions and ulcers (4) +
Mucosal erythema (5), or  923 0.75
Vascular pattern (5), or  887 0.74
Incidental friability (5)  866 0.69
3 Erosions and ulcers (4) +
Vascular pattern (5) +
incidental friability (5), or
 1108 0.91
Incidental friability (5) +
mucosal surface (5), or
 1045 0.90
Vascular pattern (5) +
bleeding (5)
 1038 0.90
3 (Simpliﬁed I)* Erosions & Ulcers (4) +
Vascular pattern (5) +
incidental friability (4) or
 1132 0.91
Vascular pattern (5) +
bleeding (4)
 1042 0.90
3 (Simpliﬁed II)y Erosions & Ulcers (4) +
vascular pattern (3) +
bleeding (4)
 999 0.90
pR
2, the squared correlation between the logit-transformed overall severity evaluations on
VAS and linear function of predictors from the model.
*Incidental friability and bleeding descriptors simpliﬁed to four levels (levels 4 and 5
combined).
yVascular pattern simpliﬁed to three levels (levels 1, 2 and 3 combined), with incidental
friability and bleeding as in*.
AIC, Akaike Information Criterion.
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GLM model regression was based on a total of 609 assessments
of 60 separate videos, excluding second assessments of repeat
video pairs; videos with CFT and assessments from an investi-
gator with a large amount of missing data were extracted. The
best regression models using one, two and three descriptors are
detailed in table 5 (1, 2 and 3), clearly showing an increasing ﬁt
with the number of descriptors (lower AIC and higher pR
2).
Analysis of the plots of least-squares means indicated that some
levels of incidental friability and bleeding could be combined,
leading to improvement in AIC values. The best model had four
levels for erosions and ulcers and incidental friability, in combi-
nation with ﬁve levels for vascular pattern, although the model
with four levels for erosions and ulcers and bleeding and ﬁve
levels for vascular pattern had a similar pR
2 (table 5, 3 (simpli-
ﬁed I)). However, reducing the vascular pattern to three levels
only resulted in a slight loss of ﬁt, with a slightly lower AIC, but
similar pR
2 (table 5, 3 (simpliﬁed II)). The simplicity of this
model and easier deﬁnition of three levels of vascular pattern
resulted in the selection of this model.
Model selected to create the index
The selected model consists of three descriptors: erosions and
ulcers, bleeding and vascular pattern (table 6). Predicted mean
severity levels (and 95% CI) for different combinations of Likert
scale levels of the three descriptors are shown in table 7. Rela-
tionships between actual mean overall assessments of severity
(VAS) and means predicted by the model are shown in ﬁgure 4.
When individual assessments were compared with predicted
values, the pR
2 was 0.78. Since the model assigned a level of
overall severity to combinations of responses, there is no single
coefﬁcient per descriptor.
DISCUSSION
This study has determined that just three descriptors (vascular
pattern, bleeding, erosions and ulcers) are sufﬁcient to create
a model accounting for the full range of endoscopic severity
associated with UC. The UCEIS accurately predicts overall
endoscopic severity judged by a VAS, although this needs to be
validated by new investigators.
Phase 1 of the study evaluated variability in endoscopic
interpretation among specialists in IBD and established deﬁni-
tions of descriptive terms. Phase 2 deﬁned inter- and intra-
observer variation, to construct a model to compare with an
overall assessment of endoscopic severity. There was widespread
variability among specialists in the assessment of endoscopic
severity. Disagreement in phase 1 was greatest for videos cate-
gorised as ‘normal’ or ‘moderate’, with only 27% agreement for
normal appearance and 37% for moderate severity, and at best
76% agreement for ‘severe’ activity.
Phase 2 involved 30 investigators from Europe, USA and
Canada. The sample size was large: for intraobserver variation,
60 repeat pairs of 36 videos were used. For interobserver varia-
tion, there were 630 assessments of 60 videos. Assessment
design was robust: videos were stratiﬁed by clinical severity,
allowing for greater variability in the mid-range of severity
unknown to investigators, then randomly assigned with
a random order for scoring descriptors. Reproducibility of
scoring within and between investigators was modest, as
expected. Interobserver variation is not synonymous with
‘agreement’, since the latter is not corrected for chance agree-
ment and correction depends on response distribution. It is
possible (perhaps even probable) that the variation was due to
sampling error, although this could not be quantiﬁed, nor
allowed for without a substantial increase in sample size. The
order of descriptors was randomised to avoid bias, but this may
have increased variation between observers, so the descriptor
order will be constant in subsequent validations. k Values may
appear poor, but the level of agreement is typical for clinical
evaluation processes. For example, evaluating microscopic
disease activity in UC reported a k statistic of 0.20e0.42,
improving to 0.59e0.70 with a pictorial scale.
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A notable ﬁnding was that contact friability was too variable
to be further considered. The test, where closed biopsy forceps
were pushed against the mucosa to determine whether bleeding
occurred, was an construct designed to standardise assessment
of mucosal friability in the ASCEND 3 clinical trial,
6 similar to
brushing the mucosa with a cotton wool pledget.
3 ‘Incidental
friability’, bleeding from the mucosa seen during withdrawal of
the ﬂexible endoscope, was more reproducible. The concept of
mucosal friability, however, is poorly understood and always
needs explanation. It evaluates mucosal fragility, assumed to be
a feature of inﬂammation before ulceration, where bleeding
occurs after minor pressure on the mucosa.
The index (UCEIS) was developed from different combina-
tions of descriptors predicting the overall assessment of severity
judged by the investigator using a VAS. Regression techniques
established the simplest combination of descriptors most accu-
rately predicting the overall level of severity. Individual
descriptors were included as categorical variables, so that each
score for each descriptor could be explored separately, including
Table 6 UCEIS descriptors and deﬁnitions
Descriptor (score
most severe lesions)
Likert scale
anchor points Deﬁnition
Vascular pattern Normal (1) Normal vascular pattern with
arborisation of capillaries
clearly deﬁned, or with
blurring or patchy loss of
capillary margins
Patchy obliteration (2) Patchy obliteration of
vascular pattern
Obliterated (3) Complete obliteration of
vascular pattern
Bleeding None (1) No visible blood
Mucosal (2) Some spots or streaks of
coagulated blood on the
surface of the mucosa
ahead of the scope, which
can be washed away
Luminal mild (3) Some free liquid blood in
the lumen
Luminal moderate
or severe (4)
Frank blood in the lumen
ahead of endoscope or
visible oozing from mucosa
after washing intraluminal
blood, or visible oozing from
a haemorrhagic mucosa
Erosions and
ulcers
None (1) Normal mucosa, no visible
erosions or ulcers
Erosions (2) Tiny (# 5mm) defects in
the mucosa, of a white or
yellow colour with a ﬂat
edge
Superﬁcial ulcer (3) Larger (>5 mm) defects in
the mucosa, which are discrete
ﬁbrin-covered ulcers in
comparison with erosions,
but remain superﬁcial
Deep ulcer (4) Deeper excavated defects in
the mucosa, with a slightly
raised edge
Additional ﬁles indicating the levels of the UCEIS are available online only.
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models captured 55e75% of the variability in the overall eval-
uation (table 5). However, several three-descriptor models
captured 90e91% of variability, which is a high level of
predictability for overall severity assessment. All three-descriptor
models included erosions and ulcers. Plots of least-squares means
showed that levels on the Likert scale for two of the descriptors
(incidental friability and bleeding) could be compressed (from
ﬁve to four levels) without loss of predictability. Compression of
the Likert scale for vascular pattern (to three levels) resulted in
some loss of ﬁt, but a pragmatic deﬁnition of a fourth level of
vascular pattern was impracticable, so this was accepted. This
left two leading three-descriptor models, including incidental
friability, or bleeding. The latter captured 90% of the variability
(pR
2¼0.90) and the former 91% (pR
2¼0.91), so the choice could
not be made on statistical grounds alone. The panel reconvened
and decided to include bleeding on the basis of clinical relevance
and simplicity.
The terms vascular pattern and bleeding are of course included
in the Baron index. Where the UCEIS differs is to deﬁne different
levels for each of three descriptors, to exclude friability and to
apply precise deﬁnitions. In theory there are 48 (43433)
possible response combinations to the three items. The ﬁnal
index can only assign a value to a fraction of combinations, since
some will not be seen in practice and others will be combined
after statistical analysis. Validation of potential grades is in
progress, but remission might be deﬁned as level 1 for all three
descriptors (allowing blurring or loss of capillary margins with
a recognisable vascular pattern, no visible bleeding and no
erosions or ulceration). On the other hand, ‘severe disease’ might
be deﬁned as a level of at least 3 for vascular pattern and
bleeding, with 2 for erosions and ulcers. Such an approach is
Table 7 Predicted mean severity index and potential UCEIS grade according to different combinations of Likert scale levels of each of the three
descriptors
Erosions and
ulcers Bleeding
Vascular
pattern
Predicted severity
on a scale 0e100 (95% CI)
Erosions and
ulcers Bleeding
Vascular
pattern
Predicted severity
on a scale 0e100 (95% CI)
1 1 1 4 (3 to 6) 3 1 1 39 (17 to 67)
1 1 2 18 (15 to 21) 3 1 2 44 (34 to 55)
1 1 3 28 (24 to 34) 3 1 3 60 (53 to 65)
1 2 1 9 (4 to 20) 3 2 1 52 (26 to 77)
1 2 2 29 (24 to 35) 3 2 2 56 (49 to 63)
1 2 3 45 (37 to 53) 3 2 3 65 (60 to 70)
13 1 2 1 ( 7 t o 4 9 ) 33 1 *
1 3 2 41 (32 to 51) 3 3 2 64 (53 to 73)
1 3 3 56 (44 to 67) 3 3 3 73 (68 to 77)
14 1 * 34 1 *
1 4 2 54 (38 to 69) 3 4 2 59 (43 to 74)
1 4 3 67 (39 to 86) 3 4 3 80 (75 to 84)
2 1 1 8 (2 to 31) 4 1 1 52 (25 to 77)
2 1 2 25 (21 to 30) 4 1 2 61 (41 to 79)
2 1 3 49 (42 to 56) 4 1 3 73 (63 to 81)
2 2 1 35 (19 to 56) 4 2 1 *
2 2 2 41 (35 to 47) 4 2 2 75 (60 to 86)
2 2 3 54 (49 to 59) 4 2 3 80 (74 to 85)
2 3 1 33 (17 to 54) 4 3 1 *
2 3 2 46 (34 to 59) 4 3 2 *
2 3 3 63 (56 to 69) 4 3 3 78 (68 to 86)
24 1 * 44 1 *
2 4 2 69 (58 to 79) 4 4 2 92 (79 to 97)
2 4 3 78 (72 to 83) 4 4 3 93 (91 to 95)
The least severe combination (1 each for erosions and ulcers, bleeding and vascular pattern) predicts an index of 4 (95% CI 3 to 6), while the most severe (4 for erosions and ulcers and
bleeding, 3 for vascular pattern), predicts an index of 93 (95% CI 91 to 95) on the visual analogue scale (0e100).
*A combination of responses neither seen in the study nor predicted, since they are clinically implausible.
Figure 4 Predicted mean assessment of severity compared with
reported mean assessment of severity. To construct the index after
excluding the second assessment of repeat video pairs and the videos
with a Contact Friability Test (CFT), each of the 30 investigators
evaluated 21 independent videos, leading to 630 evaluations. Each video
was scored by 10e12 investigators, except for Mayo Clinic score
0 videos, which were scored by 15 investigators (making up the 630).
Twenty-one evaluations with missing data were excluded from the index
construction (making 609 evaluations overall). Thus, for each video,
evaluations by 10e15 investigators were available, allowing the mean of
the evaluations of overall severity to be calculated, as well as the mean
of the severity evaluations predicted from the generalised linear mixed
model using the three descriptorsdvascular pattern, bleeding and
erosions and ulcersdaccording to the levels of these predictors
reported by each investigator. VAS, visual analogue scale.
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but it is premature to deﬁne thresholds.
The ‘gold standard’ for assessing disease activity in UC should
be a diagnostic test that can accurately predict future disease
outcome, to augment clinical evaluation. Endoscopy is a surro-
gate end point and it needs to be established that the UCEIS
correlates with, and predicts, clinical outcome. Future studies
should test (head to head) whether this instrument can predict
clinical outcome better than clinical assessment (without
endoscopy) or biomarkers (eg, faecal calprotectin or lactoferrin).
The burden of proof has to be on endoscopy, as an expensive and
invasive test, to prove that it is better than non-invasive and less
expensive alternatives.
A new index for disease activity in ulcerative colitis (the
UCEIS) has been created. It illustrates that there is wide varia-
tion in the endoscopic interpretation of disease severity between
observers. Just three descriptors can be combined to account for
90% of the overall assessment of endoscopic severity judged by
a VAS. The UCEIS is undergoing independent validation with
different videos and investigators, evaluating operating proper-
ties of the index (responsiveness and reliability). Minimal
differences for this instrument remain to be evaluated, for its
role in research, training and practice.
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